Longer Investments Has Cut Its Holding in Johnson & Johnson (JNJ) by $737,748 as Shares Rose; As Iridex (IRIX) Share Value Declined, Longwood Capital Partners Lowered Holding by $315,000

IRIDEX Corporation (NASDAQ:IRIX) Logo

Longer Investments Inc decreased its stake in Johnson & Johnson (JNJ) by 23.35% based on its latest 2018Q3 regulatory filing with the SEC. Longer Investments Inc sold 5,346 shares as the company’s stock rose 5.87% while stock markets declined. The institutional investor held 17,552 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $2.43M, down from 22,898 at the end of the previous reported quarter. Longer Investments Inc who had been investing in Johnson & Johnson for a number of months, seems to be less bullish one the $360.59 billion market cap company. The stock increased 0.22% or $0.29 during the last trading session, reaching $134.45. About 7.90M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 3.75% since February 14, 2018 and is uptrending. It has outperformed by 3.75% the S&P500. Some Historical JNJ News: 17/04/2018 – J&J PLANS TO IMPLEMENT ACTIONS ACROSS GLOBAL SUPPLY CHAIN; 08/05/2018 – J&J’s Janssen: FDA Approval Marks the Fifth Indication for Darzalex, Which Is the First CD38-Directed Antibody to Be Approved Anywhere; 30/05/2018 – $SAN.FR, JNJ, MRK: Trump: In two weeks, big drug companies are going to announce a “voluntary, massive” drop in prices – ! $SAN.FR $JNJ $MRK; 16/03/2018 – J&J says it’s received a $2.1 billion bid for LifeScan diabetes business; 20/03/2018 – DOMINIC J. CARUSO TO RETIRE AS CFO OF JOHNSON & JOHNSON; 07/03/2018 – ADVISORY: JJ Ruest, CN Interim President and Chief Executive Officer, to address J.P. Morgan Aviation, Transportation & Industrials Conference on March 14; 17/04/2018 – J&J INCREASED SALES & REAFFIRMS EPS GUIDANCE; 15/05/2018 – BNY Mellon Adds Aptiv, Cuts J&J, Buys More Netflix: 13F; 11/04/2018 – Johnson & Johnson Vision Announces Revolutionary Contact Lens Innovation with ACUVUE OASYS® with Transitions® Light Intelligent Technology™; 16/05/2018 – Johnson & Johnson is courting health-conscious millennial moms by relaunching its baby shampoo

Longwood Capital Partners Llc decreased its stake in Iridex Corp (IRIX) by 2.63% based on its latest 2018Q3 regulatory filing with the SEC. Longwood Capital Partners Llc sold 52,500 shares as the company’s stock declined 51.78% with the market. The institutional investor held 1.95M shares of the electromedical & electrotherapeutic apparatus company at the end of 2018Q3, valued at $12.37 million, down from 2.00 million at the end of the previous reported quarter. Longwood Capital Partners Llc who had been investing in Iridex Corp for a number of months, seems to be less bullish one the $64.16M market cap company. The stock decreased 0.42% or $0.02 during the last trading session, reaching $4.72. About 6,919 shares traded. IRIDEX Corporation (NASDAQ:IRIX) has declined 47.56% since February 14, 2018 and is downtrending. It has underperformed by 47.56% the S&P500. Some Historical IRIX News: 03/05/2018 – Iridex Sees 2018 Rev $37M-$41M; 16/04/2018 – IRIDEX Announces Appointment of Maria Sainz and David Bruce to its Board of Directors; 03/05/2018 – Iridex 1Q Loss/Shr 31c; 08/03/2018 – IRIDEX CORP IRIX.O SEES FY 2018 REVENUE $37 MLN TO $41 MLN; 20/03/2018 – Iridex Receives CE Mark for Transilluminated Probe; 19/04/2018 – DJ IRIDEX Corporation, Inst Holders, 1Q 2018 (IRIX); 16/03/2018 – FDA: Iridex Corporation- Iridex TruFocus LIO Premiere” Laser Indirect Ophthalmoscope ( LIO ) The LIO is a headmounted i; 08/03/2018 – IRIDEX CORP – QTRLY SHR LOSS $0.44; 08/03/2018 – Iridex 4Q Rev $10.2M; 20/03/2018 – IRIDEX GETS CE MARK FOR TRANSILLUMINATED PROBE

More notable recent IRIDEX Corporation (NASDAQ:IRIX) news were published by: Globenewswire.com which released: “IRIDEX Issues Voluntary Recall of TruFocus LIO Premiereâ„¢ Laser Indirect Ophthalmoscope – GlobeNewswire” on February 23, 2018, also Seekingalpha.com with their article: “IRIDEX Corporation (IRIX) CEO William Moore on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” published on November 04, 2018, Globenewswire.com published: “IRIDEX Announces Appointment of Robert E. Grove, Ph.D. to its Board of Directors – GlobeNewswire” on October 15, 2018. More interesting news about IRIDEX Corporation (NASDAQ:IRIX) were released by: Nasdaq.com and their article: “Longwood Capital Partners LLC Buys ACADIA Pharmaceuticals Inc, Viveve Medical Inc, Biocryst … – Nasdaq” published on May 15, 2017 as well as Nasdaq.com‘s news article titled: “Earnings Season Shows Strong Revenue Momentum – Nasdaq” with publication date: July 27, 2018.

Since September 14, 2018, it had 7 buys, and 0 sales for $671,654 activity. $45,878 worth of IRIDEX Corporation (NASDAQ:IRIX) was bought by Grove Robert Earle. PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE had bought 70,000 shares worth $420,000.

Analysts await IRIDEX Corporation (NASDAQ:IRIX) to report earnings on March, 14. They expect $-0.25 EPS, up 43.18% or $0.19 from last year’s $-0.44 per share. After $-0.26 actual EPS reported by IRIDEX Corporation for the previous quarter, Wall Street now forecasts -3.85% EPS growth.

Longwood Capital Partners Llc, which manages about $280.35 million US Long portfolio, upped its stake in Assembly Biosciences Inc (NASDAQ:ASMB) by 782,500 shares to 930,000 shares, valued at $34.54 million in 2018Q3, according to the filing. It also increased its holding in Biohaven Pharmactl Hldg Co L by 78,700 shares in the quarter, for a total of 132,500 shares, and has risen its stake in Xenon Pharmaceuticals Inc.

Among 4 analysts covering IRIDEX (NASDAQ:IRIX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. IRIDEX had 7 analyst reports since January 26, 2016 according to SRatingsIntel. The rating was initiated by Roth Capital with “Buy” on Wednesday, December 21. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, January 4 report. The stock of IRIDEX Corporation (NASDAQ:IRIX) earned “Buy” rating by Singular Research on Tuesday, January 26. TH Capital initiated the shares of IRIX in report on Wednesday, December 21 with “Buy” rating. The stock of IRIDEX Corporation (NASDAQ:IRIX) has “Buy” rating given on Sunday, February 25 by Roth Capital.

Investors sentiment increased to 1.78 in Q3 2018. Its up 0.98, from 0.8 in 2018Q2. It increased, as 2 investors sold IRIX shares while 7 reduced holdings. 6 funds opened positions while 10 raised stakes. 7.05 million shares or 30.11% more from 5.42 million shares in 2018Q2 were reported. Thompson Davis &, a Virginia-based fund reported 500 shares. The Germany-based Deutsche Financial Bank Ag has invested 0% in IRIDEX Corporation (NASDAQ:IRIX). Bridgeway reported 81,500 shares or 0.01% of all its holdings. Jpmorgan Chase & holds 69 shares or 0% of its portfolio. California Employees Retirement System holds 0% or 32,100 shares in its portfolio. Blackrock reported 0% stake. Vanguard Grp Inc Incorporated stated it has 0% in IRIDEX Corporation (NASDAQ:IRIX). Ingalls & Snyder Lc invested 0.01% in IRIDEX Corporation (NASDAQ:IRIX). 224,238 are owned by Lyon Street Ltd Liability Corp. Finemark Comml Bank And Tru has 36,365 shares. Royal Savings Bank Of Canada owns 27 shares or 0% of their US portfolio. Morgan Stanley holds 0% or 42,124 shares in its portfolio. Blair William & Company Il owns 43,600 shares. Driehaus Capital Mgmt Limited Liability Company holds 0.05% in IRIDEX Corporation (NASDAQ:IRIX) or 280,000 shares. Eidelman Virant Capital reported 152,193 shares.

Since August 27, 2018, it had 3 buys, and 8 insider sales for $79.44 million activity. 8,441 shares were sold by Kapusta Ronald A, worth $1.23M. Fasolo Peter sold $24.41M worth of Johnson & Johnson (NYSE:JNJ) on Monday, December 3. Shares for $4.41 million were sold by Sneed Michael E on Friday, November 23. $38.60 million worth of Johnson & Johnson (NYSE:JNJ) shares were sold by Gorsky Alex. On Friday, December 14 PEREZ WILLIAM D bought $133,910 worth of Johnson & Johnson (NYSE:JNJ) or 1,000 shares. 40,000 Johnson & Johnson (NYSE:JNJ) shares with value of $5.77 million were sold by Duato Joaquin.

Longer Investments Inc, which manages about $167.11M and $103.86M US Long portfolio, upped its stake in Ishares Nasdaq Biotechnology (IBB) by 8,603 shares to 23,637 shares, valued at $2.88M in 2018Q3, according to the filing.

Among 25 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 4 Sell and 9 Hold. Therefore 48% are positive. Johnson & Johnson had 111 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, October 17 by Credit Suisse. The stock has “Strong-Buy” rating by Vetr on Monday, August 31. Jefferies maintained Johnson & Johnson (NYSE:JNJ) on Wednesday, October 18 with “Buy” rating. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by S&P Research on Wednesday, October 14. Jefferies maintained it with “Buy” rating and $16100 target in Friday, March 23 report. The stock of Johnson & Johnson (NYSE:JNJ) has “Neutral” rating given on Tuesday, February 27 by Citigroup. The firm has “Sell” rating by Goldman Sachs given on Wednesday, September 20. The firm has “Neutral” rating given on Wednesday, April 20 by Goldman Sachs. The stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given on Friday, October 6 by Cowen & Co. The firm has “Neutral” rating by JP Morgan given on Tuesday, January 2.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Benzinga.com which released: “Analysts Stand By Johnson & Johnson Despite Earnings Pullback (NYSE:JNJ) – Benzinga” on January 23, 2019, also Zacks.com with their article: “Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy? – Zacks.com” published on January 15, 2019, Seekingalpha.com published: “Sri Lanka halts imports of J&J Baby Powder – Seeking Alpha” on January 31, 2019. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Johnson & Johnson: P/E Matters – Seeking Alpha” published on January 17, 2019 as well as Benzinga.com‘s news article titled: “Johnson & Johnson Wins FDA Panel Backing For Nasal Spray Depression Drug; PDUFA Date Awaits (NYSE:JNJ) – Benzinga” with publication date: February 13, 2019.

Investors sentiment increased to 1.05 in 2018 Q3. Its up 0.08, from 0.97 in 2018Q2. It improved, as 43 investors sold JNJ shares while 748 reduced holdings. 115 funds opened positions while 719 raised stakes. 1.70 billion shares or 7.91% less from 1.84 billion shares in 2018Q2 were reported. Hamel Associates has 3.98% invested in Johnson & Johnson (NYSE:JNJ). Westpac reported 0% of its portfolio in Johnson & Johnson (NYSE:JNJ). Janney Mgmt reported 1.07% stake. Cleararc Capital has invested 1.12% in Johnson & Johnson (NYSE:JNJ). 14,148 were reported by First City Capital Mgmt. Garland Mgmt accumulated 42,537 shares. Jefferies Gru Lc invested in 49,706 shares. Lawson Kroeker Investment Management Inc Ne reported 78,128 shares. Nelson Roberts Invest Advsrs Limited Liability Company holds 6,228 shares or 0.2% of its portfolio. Altfest L J & holds 18,628 shares. Obermeyer Wood Counsel Lllp owns 17,715 shares. Fincl Advisory Gp holds 0.22% in Johnson & Johnson (NYSE:JNJ) or 6,121 shares. Ironwood Inv Limited Liability Com accumulated 4,383 shares. Burns J W Inc Ny stated it has 57,804 shares or 1.88% of all its holdings. Moreover, Blue Fincl Cap Inc has 1.39% invested in Johnson & Johnson (NYSE:JNJ) for 20,468 shares.

IRIDEX Corporation (NASDAQ:IRIX) Institutional Positions Chart